CN115932250B - 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 - Google Patents
一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 Download PDFInfo
- Publication number
- CN115932250B CN115932250B CN202310011146.5A CN202310011146A CN115932250B CN 115932250 B CN115932250 B CN 115932250B CN 202310011146 A CN202310011146 A CN 202310011146A CN 115932250 B CN115932250 B CN 115932250B
- Authority
- CN
- China
- Prior art keywords
- reaction
- phosphatidylserine
- prothrombin
- aps
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 30
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 26
- 238000002038 chemiluminescence detection Methods 0.000 title claims abstract description 11
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 61
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 61
- 229940039716 prothrombin Drugs 0.000 claims abstract description 61
- 238000006243 chemical reaction Methods 0.000 claims abstract description 58
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 47
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000011324 bead Substances 0.000 claims abstract description 34
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940070710 valerate Drugs 0.000 claims abstract description 10
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000004913 activation Effects 0.000 claims abstract description 9
- OYBOVXXFJYJYPC-UHFFFAOYSA-N 3-azidopropan-1-amine Chemical compound NCCCN=[N+]=[N-] OYBOVXXFJYJYPC-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 102000015439 Phospholipases Human genes 0.000 claims abstract description 6
- 108010064785 Phospholipases Proteins 0.000 claims abstract description 6
- 230000001681 protective effect Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 40
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 238000011033 desalting Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims 1
- 238000003149 assay kit Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 29
- 239000002244 precipitate Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000003761 preservation solution Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 230000003429 anti-cardiolipin effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241001523209 Antissa Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 206010063663 Neuropsychiatric lupus Diseases 0.000 description 1
- 241001072961 Pogostemon Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000003186 anti-thromboplastin Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 101150050191 apl gene Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310011146.5A CN115932250B (zh) | 2023-01-05 | 2023-01-05 | 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310011146.5A CN115932250B (zh) | 2023-01-05 | 2023-01-05 | 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115932250A CN115932250A (zh) | 2023-04-07 |
CN115932250B true CN115932250B (zh) | 2023-06-06 |
Family
ID=85838534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310011146.5A Active CN115932250B (zh) | 2023-01-05 | 2023-01-05 | 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115932250B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117288948B (zh) * | 2023-06-19 | 2024-06-04 | 无锡嘉润诊断技术有限公司 | 抗凝血酶原抗体检测试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104637A1 (en) * | 2006-01-31 | 2009-04-23 | Ismagilov Rustem F | Method and Apparatus for Assaying Blood Clotting |
CN109425740A (zh) * | 2017-08-31 | 2019-03-05 | 江苏麦得科生物科技有限公司 | 异常凝血酶原(pivka-ⅱ)磁微粒化学发光免疫分析测定试剂盒及其制备方法 |
CN111323577B (zh) * | 2020-03-10 | 2022-05-03 | 郑州安图生物工程股份有限公司 | 一种抗心磷脂抗体IgG磁微粒化学发光免疫检测试剂盒 |
CN112255416A (zh) * | 2020-09-29 | 2021-01-22 | 北京利德曼生化股份有限公司 | 使用磁微粒化学发光定量检测hbp的试剂盒及其制备、检测方法 |
-
2023
- 2023-01-05 CN CN202310011146.5A patent/CN115932250B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN115932250A (zh) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2978998C (en) | Method and kit for measuring component to be assayed in specimen | |
CN115932250B (zh) | 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 | |
US7888057B2 (en) | Immunological assay for plasmin-digested products of stabilized fibrin | |
CN113804896A (zh) | 测定人体血清中白介素-8含量的磁微粒化学发光试剂盒 | |
CN116068172B (zh) | 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 | |
US20220018856A1 (en) | Antibody conjugate | |
CA2599731A1 (en) | Quantification of proteins | |
JP3537331B2 (ja) | Iv型コラーゲンの免疫測定法及び試薬 | |
CN110988325A (zh) | 封闭剂及包含该封闭剂的试剂盒 | |
JPH02500164A (ja) | 新規なイムノアツセイ方法 | |
EP3760641A1 (en) | Monoclonal antibody against apoa4, immunoassay method, and kit for measurement | |
CN111929440A (zh) | 一种基于磁微粒化学发光免疫法检测dnase1l3的方法 | |
JPH01165960A (ja) | トランスフェリンの測定方法 | |
CN114686443B (zh) | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 | |
CN114686444B (zh) | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 | |
JPS60249058A (ja) | Atlウイルス抗体の測定方法および試薬 | |
CN117285635B (zh) | 抗肝素结合蛋白的单克隆抗体组合物及应用 | |
CN113912719B (zh) | 检测小鼠白介素6的单克隆抗体及其制备方法和应用 | |
WO2021193763A1 (ja) | ヒトiv型コラーゲン7sドメインを含む断片の測定方法及びこれに用いるためのキット | |
Ogawa et al. | Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles | |
CN116643051A (zh) | 一种人钙结合蛋白s100a8检测试剂盒 | |
JP3536191B2 (ja) | ヒトラクトフェリンの分析方法、感染症のスクリーニング方法及びスクリーニング用キット | |
CN118130810A (zh) | 一种检测外周血自身免疫抗体aqp4的组合物及试剂盒 | |
CN116973577A (zh) | 一种检测抗β2糖蛋白1抗体的测定试剂盒及其制备方法和检测方法 | |
JPH07117534B2 (ja) | ヒトプロテインsに対するモノクローナル抗体を用いた免疫学的測定試薬及びキット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 205, Building B, No. 36 Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, China (Zhangjiagang Free Trade Zone Science and Technology Entrepreneurship Park) Patentee after: Suzhou Diyalaibo Biotechnology Co.,Ltd. Country or region after: Zhong Guo Address before: Room 205, Building B, No. 36, Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, 215634 Patentee before: Suzhou Huizhong Biotechnology Co.,Ltd. Country or region before: Zhong Guo |